Pluvicto (Lutetium-177-PSMA-617)
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for Pluvicto (Lutetium-177-PSMA-617), covering 2022-12-13 to 2026-01-28. Get the full timeline:
Most recent: Clinical Trial Update: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer [Phase 2]